← FDA DRUG APPROVALS

FDA ANDA · ANDA079244

LORAZEPAM

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA079244
TYPE
ANDA
ORIGINAL APPROVAL
2009-04-28
LATEST ACTION
2016-07-06
ROUTE
ORAL
DOSAGE FORM
CONCENTRATE
MARKETING STATUS
Discontinued

Products

LORAZEPAMDiscontinued
LORAZEPAM 2MG/ML · CONCENTRATE · ORAL

Approval history

2016-07-06Labeling · Supplement 5 · standardAP
2009-04-28OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →